Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial
暂无分享,去创建一个
E. Antman | R. Giugliano | E. Braunwald | Raymond Miller | M. Mercuri | J. Weitz | O. Yin | D. Morrow | C. Ruff | K. Truitt
[1] F. Lee,et al. Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects , 2013, Clinical pharmacology in drug development.
[2] T. Buclin,et al. Therapeutic Drug Monitoring of Imatinib , 2012, Clinical Pharmacokinetics.
[3] V. Fuster,et al. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber , 2007, Thrombosis and Haemostasis.
[4] F. Rosendaal,et al. Thrombosis in the Young: Epidemiology and Risk Factors. A Focus on Venous Thrombosis , 1997, Thrombosis and Haemostasis.
[5] T. Shibano,et al. DU‐176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles , 2008, Journal of thrombosis and haemostasis : JTH.
[6] E. Antman,et al. Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. , 2016, JAMA cardiology.
[7] S. Ogawa,et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. , 2012, Circulation journal : official journal of the Japanese Circulation Society.
[8] J. Vilo,et al. DosOpt: A Tool for Personalized Bayesian Dose Adjustment of Vancomycin in Neonates , 2017, Therapeutic drug monitoring.
[9] P. Dobesh,et al. Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities , 2015, Drugs.
[10] Raymond Miller,et al. Population Pharmacokinetics and Dose–Exposure Proportionality of Edoxaban in Healthy Volunteers , 2014, Clinical Drug Investigation.
[11] N. Holford. A Time to Event Tutorial for Pharmacometricians , 2013, CPT: pharmacometrics & systems pharmacology.
[12] E. Antman,et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation , 2012, Thrombosis and Haemostasis.
[13] Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation , 2008, Stroke.
[14] E. Antman,et al. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial , 2016, Journal of the American Heart Association.
[15] G. Wool,et al. Pathology consultation on anticoagulation monitoring: factor X-related assays. , 2013, American journal of clinical pathology.
[16] M. Laposata,et al. Test of the month: The chromogenic antifactor Xa assay , 2012, American journal of hematology.
[17] H. Masumoto,et al. Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers , 2010, Journal of clinical pharmacology.
[18] E. Antman,et al. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial , 2016, Journal of the American Heart Association.
[19] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[20] J. Mendell,et al. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. , 2013, British journal of clinical pharmacology.
[21] J. Weitz,et al. Coagulation assays. , 2005, Circulation.
[22] Raymond Miller,et al. Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial , 2016, Clinical Pharmacokinetics.
[23] Anna-Karin Hamberg,et al. A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children , 2015, BMC Medical Informatics and Decision Making.
[24] G. Raskob,et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.
[25] E. Antman,et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.
[26] E. Antman,et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial , 2015, The Lancet.
[27] R. Kim,et al. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. , 2013, The Canadian journal of cardiology.